Press releases
- Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
- Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- Savara to Present at the Jefferies Global Healthcare Conference
- Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
- Savara Announces New Employment Inducement Grant
- Savara Reports First Quarter 2024 Financial Results and Provides Business Update
- Savara to Present at the Citizens JMP Life Sciences Conference
More ▼
Key statistics
On Friday, Savara Inc (YB4P:MUN) closed at 4.00, -20.79% below its 52-week high of 5.05, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.00 |
---|---|
High | 4.00 |
Low | 4.00 |
Bid | 4.06 |
Offer | 4.14 |
Previous close | 4.02 |
Average volume | 1.02k |
---|---|
Shares outstanding | 164.42m |
Free float | 156.65m |
P/E (TTM) | -- |
Market cap | 728.40m USD |
EPS (TTM) | -0.3848 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:08 BST.
More ▼